腹水症状清单-7是评估托伐普坦在肝硬化腹水患者中有效性的有价值的工具。,Experimental and Therapeutic Medicine

当前位置： X-MOL 学术 › Exp. Ther. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

腹水症状清单-7是评估托伐普坦在肝硬化腹水患者中有效性的有价值的工具。
Experimental and Therapeutic Medicine ( IF 2.4 ) Pub Date : 2020-11-10 , DOI: 10.3892/etm.2020.9462
Hideto Kawaratani ₁ , Kei Moriya ₁ , Tadashi Namisaki ₁ , Naotaka Shimozato ₁ , Kosuke Kaji ₁ , Hiroaki Takaya ₁ , Yukihisa Fujinaga ₁ , Yasuhiko Sawada ₁ , Shinya Sato ₁ , Soichiro Saikawa ₁ , Takuya Kubo ₁ , Takemi Akahane ₁ , Hiroshi Fukui ₁ , Hitoshi Yoshiji ₁

Affiliation

肝硬化患者经常出现非特异性症状，并报告其生活质量（QOL）严重降低。该疾病的潜在机制是多因素的，可能是该疾病特有的或与肝脏直接相关。但是，肝硬化腹水的主要问题是QOL降低。因此，在本研究中，采用腹水症状量表7（ASI-7）问卷主观评估托伐普坦给药后肝硬化腹水患者的症状。在2013年12月至2018年4月之间，接受托伐普坦（3.75-7.5 mg /天）和常规利尿剂治疗的69例肝硬化腹水肝硬化肝硬化患者接受了评估。随访7天后进行了随访评估托伐普坦治疗，在研究的第1天和第8天使用了ASI-7。经过平稳的7天托伐普坦治疗方案后，有49位患者（71.0％）体重减轻了> 1.5 kg，这些患者被称为缓解者，ASI-7得分的变化与体重变化相关。相反，尿量的变化与ASI-7评分的变化不相关。与没有反应者相比，在7天后，反应者的ASI-7得分降低幅度更大（P <0.01）。还发现托伐普坦给药后ASI-7评分与体重相关。总之，ASI-7能够准确反映出体重的变化，但不能准确反映出尿量，该研究结果突出了ASI-7在评估肝硬化腹水中的托拉普坦的腹水量和有效性方面的价值。

"点击查看英文标题和摘要"

Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.

Patients with liver cirrhosis frequently experience non-specific symptoms and report severe reductions in their quality of life (QOL). The underlying mechanisms of the disease are multifactorial that may be specific to the disease or directly related to the liver. The major concern of liver cirrhosis with ascites, however, is the decreased QOL. Therefore, in the present study, the Ascites Symptom Inventory-7 (ASI-7) questionnaire was applied to subjectively evaluate the symptoms in patients with cirrhotic ascites following tolvaptan administration. In total, 69 patients with liver cirrhosis with ascites hospitalized to Nara Medical University were evaluated after being treated with tolvaptan (3.75-7.5 mg/day) and conventional diuretics between December 2013 and April 2018. A follow-up assessment was conducted 7 days after tolvaptan treatment, whilst ASI-7 was used on days 1 and 8 of the study. After an uneventful 7-day tolvaptan treatment regimens, 49 patients (71.0%) lost >1.5 kg of their body weight, who were referred to as responders, with the change in the ASI-7 score being found to correlate with the body weight change. By contrast, changes in urine volume did not correlate with those in the ASI-7 score. The responders experienced a greater reduction in the ASI-7 score after 7 days compared with those in the non-responders (P<0.01). ASI-7 scores were also found to correlate with body weight after tolvaptan administration. In conclusion, ASI-7 accurately reflected changes in body weight but not urine volume and results of the study highlighted the value of ASI-7 in the evaluation of ascitic volume and effectiveness of tolvaptan in cirrhotic ascites. The present clinical trial was registered onto the UMIN-Clinical Trial Registry on 1st March 2014 (registration no. UMIN000013095).

更新日期：2020-12-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南